SLU-PP-332 + BAM15 (Capsules)

This combination of SLU-PP-332 + BAM15 formulation pairs two distinct research compounds designed to investigate complementary metabolic and mitochondrial signaling pathways. SLU-PP-332 is a synthetic estrogen-related receptor (ERR) pan-agonist developed at Saint Louis University for studying exercise-mimetic responses and metabolic regulation [1]. BAM15 is a novel mitochondrial uncoupler discovered and characterized for its selective effects on mitochondrial respiration without depolarizing the plasma membrane [2]. Together, combination of SLU-PP-332 + BAM15 compounds provide a comprehensive tool set for research into mitochondrial function, metabolic flexibility, energy expenditure mechanisms, and cellular adaptation responses typically associated with endurance training. Both are supplied exclusively for controlled laboratory research use.

Chemical Structure and Identification of SLU-PP-332 + BAM15

SLU-PP-332

• Compound Name: SLU-PP-332 (ERR Pan-Agonist)
• Per Capsule: 250 mcg per capsule
• Molecular Formula: C₁₈H₁₄N₂O₂
• Molecular Weight: 290.32 g/mol
• CAS Number: 303760-60-3

BAM15

• Compound Name: BAM15
• Per Capsule: 50 mg per capsule
• Molecular Formula: C₁₆H₁₀F₂N₆O
• Molecular Weight: 340.29 g/mol
• CAS Number: 210302-17-3

Research Applications for SLU-PP-332 + BAM15

• Exercise Mimetic Research: Investigation of ERR-mediated cellular adaptations to endurance training-like stimuli [1]
• Mitochondrial Function: Mechanistic studies of BAM15-induced uncoupling and effects on respiratory kinetics and ATP production [2]
• Metabolic Flexibility: Examination of oxidative fiber composition, fatty acid oxidation capacity, and fuel substrate utilization [3]
• Energy Expenditure Research: Combined investigation of ERR agonism and mitochondrial uncoupling effects on cellular energy utilization [1][2]
• Metabolic Disease Models: Preclinical research into obesity, diabetes, and glucose homeostasis using complementary mechanistic approaches [3]
• Cellular Bioenergetics: Comprehensive evaluation of mitochondrial capacity, endothelial metabolic function, and organ protection mechanisms [4]

Reference Citations for SLU-PP-332 + BAM15

1. University of Florida/ACS Chemical Biology (2023) – Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response | https://pubmed.ncbi.nlm.nih.gov/
2. PubMed (37900126) – BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases | https://pubmed.ncbi.nlm.nih.gov/37900126/
3. PubMed (32519812) – BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control | https://pubmed.ncbi.nlm.nih.gov/32519812/
4. PubMed (24634817) – Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane | https://pubmed.ncbi.nlm.nih.gov/24634817/
5. PubMed (40429748) – Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on BAM15 | https://pubmed.ncbi.nlm.nih.gov/40429748/
6. PubMed (34062536) – BAM15, a Mitochondrial Uncoupling Agent, Attenuates Inflammation in the LPS Injection Mouse Model | https://pubmed.ncbi.nlm.nih.gov/34062536/

Important Regulatory Notice

These products are for research use only and are not intended for human consumption, therapeutic use, or diagnostic purposes. All compounds described herein have not been approved by the FDA for human use. These products are strictly intended for in vitro laboratory research and analytical purposes when conducted by qualified research professionals in licensed facilities. Users are responsible for ensuring compliance with all applicable laws regarding purchase and use of these materials.